Biosergen AS develops variants of nystatin with improved properties.
Business Model:
Revenue: $0
Employees: 1-10
Address:
City: Trondheim
State: Sor-Trondelag
Zip:
Country: Norway
Biosergen AS develops variants of nystatin with improved properties. Its pipeline products include S44HP, an antibiotic that is more potent than nystatin against several fungal pathogens; and nystatin analogues produced through manipulation of the nystatin biosynthetic genes.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 2/2016 | Grant | - | 2/2013 | Funding Round | 2 | - |
Rosetta Capital SINTEF Venture AS Rosetta Capital SINTEF Venture AS |
2/2016 | Grant | - | 2/2013 | Funding Round | 2 | - |
Rosetta Capital SINTEF Venture AS Rosetta Capital SINTEF Venture AS |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|